M L Maksimov, I A Mochkin, A K Starodubtsev. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » Angiotensin II Type 1 Receptor Blockers/administration & dosageAngiotensin II Type 1 Receptor Blockers/adverse effectsAngiotensin II Type 1 Receptor Blockers/metabolismBlood Pressure/drug effectsDrug MonitoringHeart Failure/drug therapyHeart Failure/metabolismHumansHypertension/drug therapyHypertension/metabolismRandomized Controlled Trials as TopicReceptors, Angiotensin/metabolismRenal Insufficiency/drug therapyRenal Insufficiency/metabolismRenin-Angiotensin System/drug effectsTetrazoles/administration & dosageTetrazoles/adverse effectsTetrazoles/metabolismValine/administration & dosageValine/adverse effectsValine/analogs & derivativesValine/metabolismValsartanWater-Electrolyte Balance/drug effects
Substances： See more » Angiotensin II Type 1 Receptor BlockersReceptors, AngiotensinTetrazolesValsartanValine
Year: 2011 PMID： 21942964
Source DB: PubMed Journal: Kardiologiia ISSN： 0022-9040 Impact factor: 0.395